Skip to content

Current Debt at other companies

Royalty Pharma logo
Royalty PharmaRPRX
$380M-61.9%
Xencor logo
XencorXNCR
$26.41M-49.7%
Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
$2.31B-35.1%
AbbVie logo
AbbVieABBV
$0-100%
BioCryst Pharmaceuticals logo
BioCryst PharmaceuticalsBCRX
$1.24M-31.2%
BridgeBio Pharma logo
BridgeBio PharmaBBIO

Other financials

Income statement

See full
Revenue$12.3M-22.6%
Operating income-$480.0K-108%
Net income$4.5M+88.6%
EPS (diluted)$0.17+183%

Balance sheet

See full
Cash & equivalents$85.6M-5.2%
Total debt$124.7M+9.0%
Total equity$92.9M+9.7%
Total assets$271.9M+27.8%

Cash flow

See full
Operating cash flow$6.1M+178%
CapEx$3.0K-29.4%
Free cash flow-$2.9M+36.0%

Valuation

See full
Market cap$745.16M+159%
Enterprise value$784.29M+151%
P/E22×
P/S15.4×+8.6×

Profitability

See full
Operating margin10.2%+5.5pp
Net margin69.6%+64.0pp
FCF margin-320%-118pp

Returns & leverage

See full
Return on equity38.1%+35.2pp
Debt / equity1.3×0.0×
Current ratio3.6×-2.0×

Where this comes from

Reported directly by XOMA Corporation in its filing.

Tagged under the XBRL concept us-gaap:LongTermDebtCurrent.

The official record: XOMA Corporation’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about XOMA Corporation's current debt.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is XOMA Corporation's current debt?
XOMA Corporation (XOMA) reported current debt of $14.01M in Q1 2026.
How has XOMA Corporation's current debt changed year-over-year?
XOMA Corporation's current debt increased by 2.3% year-over-year, from $13.7M to $14.01M.
What is the long-term trend for XOMA Corporation's current debt?
Over 3 years (2020 to 2025), XOMA Corporation's current debt has grown at a 15.7% compound annual growth rate (CAGR), from $8.09M to $12.53M.
What does current debt mean?
The portion of long-term debt maturing within the next 12 months, requiring refinancing or repayment from operating cash flows.